Why is "Rapastinel" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-19 21:17:39
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Rapastinel entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-19 and was most recently seen on 2026-08-19.
Wikipedia Overview
Rapastinel is a novel antidepressant that was under development by Allergan as an adjunctive therapy for the treatment of treatment-resistant depression. It is a centrally active, intravenously administered amidated tetrapeptide that acts as a novel and selective modulator of the NMDA receptor. The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to enhance NMDA receptor-mediated signal transduction and synaptic plasticity.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Allergan’s NMDA drug rapastinel flops in phase 3 depression studies - Fierce Biotech
-
ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice - Nature
-
Allergan’s depression drug rapastinel fails in Phase III trials - Clinical Trials Arena
-
Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD) - PR Newswire
-
Allergan depression drug fails in setback for turnaround - BioPharma Dive
-
Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD) - PR Newswire
-
GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects - Nature
-
How new antidepressants are changing the landscape of depression treatment - News-Medical
-
Drug-digital dual therapy for depression starts phase 2 - pharmaphorum
-
Early Test Shows: Experimental Drug May Have Potential to Relieve OCD Symptoms Quickly and with Few Side Effects - Brain & Behavior Research Foundation
-
Allergan's failed depression drug shows promise in opioid withdrawal - Fierce Biotech
-
Experimental drug may ease opioid withdrawal symptoms - Medical News Today
-
A promising sign for ‘Pfallergan’ pipeline as Allergan depression med nabs ‘breakthrough’ - BioPharma Dive
-
Allergan acquires NMDA depression drug from Aptinyx collaboration - Fierce Biotech
-
Allergan Successfully Completes Naurex Acquisition - PR Newswire
-
2019’s top 15 clinical trial flops (and a flip-flop) - Fierce Biotech
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.